Figure 2: HDL from ESRD patients are defective in medicating RCT in vivo. | Scientific Reports

Figure 2: HDL from ESRD patients are defective in medicating RCT in vivo.

From: High density lipoprotein (HDL) particles from end-stage renal disease patients are defective in promoting reverse cholesterol transport

Figure 2

Mice injected with macrophage foam cells loaded with radioactively labelled 3H-cholesterol were infused with either PBS, control HDL or ESRD-HDL as detailed in methods. (a) Mass changes in plasma total cholesterol, (b) mass changes in plasma free cholesterol, (c) appearance of the 3H-cholesterol tracer in plasma, (d) mass fecal neutral sterol excretion over 48 h, (e) mass fecal bile acid excretion over 48 h, (f) fecal 3H-cholesterol tracer excretion within neutral sterols, (g) fecal 3H-cholesterol tracer excretion within bile acids. Data are presented as means ± SEM, n = 6–8 mice/group. *p < 0.05, **p < 0.01.

Back to article page